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http://dxObjective: We report our first-in-human clinical experience in the use of the new version of the EMBOL-X
intra-aortic filter (Edwards Lifesciences Corporation, Irvine, Calif) to capture embolic material during trans-
aortic transcatheter aortic valve implantation and cardiac surgery.
Method: Five patients were enrolled into the first-in-human clinical assessment of the new version of the EMBOL-
X intra-aortic filter. Three patients underwent coronary artery bypass grafting, and 2 patients underwent transaortic
transcatheter aortic valve implantation. During coronary artery bypass grafting, the filter was deployed before
clamping of the aorta and removal of the aortic clamp. In contrast, the filter was deployed before aortic puncture
for transaortic transcatheter aortic valve implantation and kept in the aorta throughout the entire procedure.
Results: The filter introducer sheath and filter were easily placed and removed without difficulty. There were no
complications related to the use of the filter. Postoperative examination of the retrieved filters revealed the pres-
ence of multiple microemboli in the filters from all 5 cases. Histologic study revealed various kinds of tissue and
thrombus.
Conclusions: This first-in-human clinical experience has demonstrated the safety and feasibility of using the
new version of the EMBOL-X intra-aortic filter during either cardiac surgery or transaortic transcatheter aortic
valve implantation. We believe that the combination of the transaortic approach without aortic arch manipula-
tion and the use of the EMBOL-X filter with a high capture rate is a promising strategy to reduce the incidence of
embolic complications during transcatheter aortic valve implantation. (J Thorac Cardiovasc Surg
2014;148:2905-10)A
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DAtherosclerotic disease of the aorta is common and associ-
ated with particulate emboli during aortic manipulation,
clamping, and declamping.1-4 Neurologic complications
have been demonstrated to be directly linked to embolism
during cardiac surgery.5,6 Transcatheter aortic valve
implantation (TAVI) is a minimally invasive technology
that has been accepted as an alternative treatment for
symptomatic severe aortic stenosis in high-risk patients.
Stroke, however, remains a concern and is associated with
significant perioperative morbidity and mortality. Stroke
has been reported in 2% to 11% of patients7-10 and is
associated with a 3.5-fold increased mortality within the
first 30 days.11 In the randomized PARTNER trial, stroke
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The Journal of Thoracic and CarTAVI than after conventional aortic valve replacement
(AVR).12 Magnetic resonance imaging has revealed new ce-
rebral ischemic lesions after TAVI in as many as 84% of
patients.13
Filter systems have been suggested to reduce the amount
of solid cerebral embolic material. Clinical studies have
demonstrated that the older version of the EMBOL-X
intra-aortic filter (Edwards Lifesciences Corporation, Ir-
vine, Calif) effectively captures embolic material14-17 and
may decrease postoperative neurologic complications
after on-pump coronary artery bypass grafting (CABG).18
The older version of the EMBOL-X intra-aortic filter is
attached to a large aortic cannula, which is designed for
use during cardiac surgery. The new version of the
EMBOL-X intra-aortic filter (Edwards Lifesciences) has
been modified to be suitable for standard cardiac surgery,
ministernotomy cardiac surgery, and transaortic TAVI. We
report our first-in-human clinical experience in using the
new version of the EMBOL-X intra-aortic filter to capture
embolic material during both transaortic TAVI and cardiac
surgery.MATERIALS AND METHODS
New Version of EMBOL-X Intra-Aortic Filter
The new version of the EMBOL-X intra-aortic filter is no longer
attached to a 24F intra-aortic cannula and therefore requires a much smallerdiovascular Surgery c Volume 148, Number 6 2905
Abbreviations and Acronyms
AVR ¼ aortic valve replacement
CABG ¼ coronary artery bypass grafting
CPB ¼ cardiopulmonary bypass
TAVI ¼ transcatheter aortic valve implantation
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Dintroducer sheath (17F; Figure 1). The device includes an EMBOL-X intra-
aortic filter and introducer sheath. The filter consists of a heparin-coated,
120-mm polyester mesh, surrounded by a flexible nitinol frame designed
to conform to the interior of the aorta. The available filter sizes range
from 26 to 37 mm (Figure 2).
Techniques for Insertion of the Filter
Figure 3 illustrates the cannulation site for an EMBOL-X introducer
sheath in the ascending aorta in patients undergoing cardiac surgery with
full sternotomy or transaortic TAVI with upper ministernotomy (manu-
brium only). During cardiac surgery, double purse-string sutures with non-
pledgeted 3-0 or 4-0 polypropylene sutures were placed in the ascending
aorta proximal to the cardiopulmonary bypass (CPB) aortic cannula site
and distal to the cardioplegic cannula site. A sufficient distance between
the filter introducer site and the cardioplegic cannula site is required for
the placement of an aortic crossclamp. If a patient with a short ascending
aorta is undergoing conventional AVR or CABG, the aortic cannulation
site for CPB should be at the proximal aortic arch to accommodate the
placement of an EMBOL-X introducer sheath, cardioplegic cannula, and
proximal anastomoses of bypass grafts (CABG) or aortotomy (AVR) in
the ascending aorta. In contrast, during transaortic TAVI the filter intro-
ducer sheath should be placed in the distal ascending aorta near the aortic
arch but proximal to the origin of the brachiocephalic artery. Furthermore,
the filter introducer sheath needs to be placed at the medial side of the
ascending aorta, which leaves more space at the lateral side of the
ascending aorta for the placement of an ASCENDRA delivery sheath forFIGURE 1. The old and new versions
2906 The Journal of Thoracic and Cardiovascular SurTAVI. Pledgeted 4-0 or 3-0 polypropylene sutures would be preferable
for double purse-string sutures for the filter introducer sheath.
The size of the distal ascending aorta was determined either by
computed tomographic scan or intraoperative direct aortic measurement.
The filter size was then selected on the basis of the measured aortic size
(Figure 2). The filter was prepared and kept in water until it was ready to
be loaded into the filter introducer sheath to minimize potential air bubbles
in the filter. During the cardiac surgery, the filter was deployed just before
clamping of the aorta and removal of the aortic clamp. In contrast, the filter
was deployed immediately before aortic puncture for transcatheter valve
procedures and was kept in the aorta throughout the entire procedure of
transaortic TAVI (insertion of 6F sheath, retrograde crossing of the aortic
valve with guide wires, insertion of ASCENDRA delivery sheath, balloon
aortic valvuloplasty, insertion and deployment of the Edwards SAPIEN
valve, and removal of the ASCENDRA delivery sheath; Figure 4). The fil-
ter has to be placed perpendicularly to the long axis of the distal ascending
aorta, achieving maximal sealing of the aortic lumen by the filter.
Patients
After informed consent was obtained, 5 patients were enrolled into this
first-in-human clinical assessment of the new version of the EMBOL-X
intra-aortic filter. Three patients underwent conventional CABG, and the
other 2 patients were accepted for transaortic TAVI. All the 5 patients
had no significant calcification in the ascending aorta, and the 2 patients un-
dergoing TAVI had significant peripheral vascular disease. None had a his-
tory of stroke. In the 3 patients undergoing CABG, single aortic
crossclamping was used for proximal anastomoses of the vein grafts.RESULTS
In each case, there was a sufficient space in the ascending
aorta for the placement of the filter introducer sheath. The
filter introducer sheath was easily placed and removed
without difficulty or complications. The filter could also
be inserted and retrieved quite smoothly through the intro-
ducer sheath. Therewere no complications related to the useof the EMBOL-X intra-aortic filter.
gery c December 2014
FIGURE 2. Description of the new version of the EMBOL-X intra-aortic filter (A) and the introducer sheath (B). OD, Outer diameter.
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Dof the filter. Determining the completeness of the sealing of
the aortic lumen by the filter was challenging, because
transesophageal echocardiographic visualization of theFIGURE 3. Placement of the EMBOL-X intra-aortic filter and other cannulas
aortic transcatheter aortic valve implantation (TAVI) (B). CPB, Cardiopulmona
The Journal of Thoracic and Cardistal ascending aorta was limited. The use of the filter
did not interfere with the usual surgical procedures. Postop-
eratively, no clinical neurologic complications, embolicin the ascending aorta during conventional cardiac surgery (A) and trans-
ry bypass.
diovascular Surgery c Volume 148, Number 6 2907
FIGURE 4. Insertion of EMBOL-X intra-aortic filter and transaortic transcatheter aortic valve implantation. A, EMBOL-X introducer sheath and filter and
ASCENDRA delivery sheath. B, Deployed filter seen on fluoroscopic image. C, Performing transcatheter aortic valve implantation.
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Devents, aortic dissections, or other complications related to
the use of the filter were observed in any case. Careful
postoperative examination of the retrieved filters revealed
the presence of multiple microemboli in the filters from
all 5 study patients (capture rate 100%). The largest
embolic debris piece was approximately 2 3 2 mm; it
was captured in the filter from a patient who underwent
CABG (Figure 5). Histologic study of the 5 captured
microemboli from 1 patient who underwent transaorticFIGURE 5. Captured embolic material during aortic crossclamping (A) and re
bypass grafting.
2908 The Journal of Thoracic and Cardiovascular SurTAVI revealed elastic arterial wall, elastic arterial wall
with intimal tissue, and fibrin platelet thrombus with
admixed red blood cells (Figure 6).
DISCUSSION
Despite advances in technology and surgical techniques
(anesthesia, CPB circuits, better materials and instrumenta-
tion, and avoidance of CPB and aortic crossclamping),
neurologic injury still occurs after both conventionalmoval of aortic crossclamp (B) from a patient undergoing coronary artery
gery c December 2014
FIGURE 6. Histologic study of 5 captured emboli from a patient undergoing transaortic transcatheter aortic valve replacement. A, Gross image of the filter.
B-F, Hematoxylin and eosin–stained slides showing elastic arterial wall (B, C, and F), elastic arterial wall and intimal tissue (D), and fibrin platelet thrombus
with admixed red blood cells (E).
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Dcardiac surgery and TAVI. The incidences of silent embolic
events after surgical AVR and TAVI have been reported to
be as great as 47%19,20 and 84%.13 Several cerebral protec-
tion devices have therefore been developed in an attempt to
reduce these adverse events. These devices are designed to
maintain normal cerebral perfusion while reducing embolic
events, either by filtration or by diversion of debris away
from the cerebral circulation. These devices include the Tri-
Guard Cerebral Protection Device (Keystone Heart Ltd,
Herzliya Pituach, Israel), the Embrella Embolic Deflector
device (Edwards Lifesciences), and the Claret Montage
Dual Filter System (Claret Medical Inc, Santa Clara, Calif).
These devices are primarily designed for the use during en-
dovascular procedures, rather than during cardiac surgery.
The first 2 devices (TriGuard and Embrella) do not remove
embolic material, and all 3 devices do not prevent embolism
to the rest of body, so renal, visceral, or peripheral vascular
embolism remains a concern with these devices.21 In
contrast, the EMBOL-X intra-aortic filter does capture
and remove embolic material, which results in a reduction
of the embolic burden in the entire body. Theoretically,
this kind of device is better than a deflector. The old version
of the EMBOL-X filter was designed for the use during con-
ventional cardiac surgery and has already been well studied.
The multi-center randomized trial comprising 1289 patients
showed a presence of emboli in 96.8% of the filtersThe Journal of Thoracic and Carremoved after the procedure, a 74% reduction of cerebral
injury in high-risk patients, and a reduction of renal compli-
cations from 24% to 14%.17 Another study, in which the
old version of the EMBOL-X filter was inserted before
aortic crossclamping or declamping, showed a microem-
bolic capture rate of 67%.22 One concern about the use of
the old version of the EMBOL-X filter has been the poten-
tial risk of iatrogenic injury to the ascending aorta, although
this was not observed in previous studies.17,22 In addition,
the use of the filter could introduce additional gaseous
microbubbles,23 a common concern for all embolic deflec-
tors and capture devices.
Generally speaking, calcification and atherosclerosis are
more commonly seen in the aortic arch than in the
ascending aorta in elderly patients. Avoiding instrumenta-
tion in the aortic arch would theoretically prevent potential
dislodgment of debris from the diseased aortic arch during
TAVI. The transaortic approach for TAVI without aortic
arch guidewires or instrumentation may decrease embolic
events relative to the transfemoral and transapical ap-
proaches for TAVI. The transaortic approach cannot, how-
ever, eliminate instrumentation in the ascending aorta.
More importantly, a considerable amount of embolic mate-
rial also emerges from the aortic valve manipulations.24
There has been a case report on the use of the old version
of the EMBOL-X intra-aortic filter during transaorticdiovascular Surgery c Volume 148, Number 6 2909
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DTAVI showing capture of multiple microemboli.25 In addi-
tion, the old device, which is attached to a large aortic can-
nula, is not amenable to use during TAVI because of limited
exposure of the ascending aorta. The new version of the
EMBOL-X intra-aortic filter system is much smaller and re-
quires a very small aortic space for its insertion. Our first-in-
human clinical experience has shown that the new version
of the EMBOL-X system can be used easily during both
conventional cardiac surgery and transaortic TAVI. No
enlargement of the upper ministernotomy is required to
accommodate the use of the filter system during transaortic
TAVI. Stabilization of the introducer sheath and filter could
be easily achieved, which might avoid injury to the aorta.
We did not observe any minor or major complications
related to the use of the device in our cases. A high capture
rate of emboli was also demonstrated in this very small case
series. As seen in all embolic protection devices, some po-
tential limitations exist, such as the introduction of air micro
emboli, residual flow around the device, and possibility of
causing damage to the vessel wall. Further optimization
of the delivery system and the filter is required to achieve
ideal sealing of the aortic lumen and maximal capture of
embolic material.CONCLUSIONS
This first-in-human clinical experience has demonstrated
the feasibility of using the new version of the EMBOL-X
intra-aortic filter during either conventional cardiac surgery
or transaortic TAVI. An upper ministernotomy (manubrium
only) is sufficient for placement of the filter during
transaortic TAVI. We believe that the combination of the
transaortic approach without aortic arch manipulation and
the use of the EMBOL-X filter with its high capture rate
appears a promising strategy to reduce the incidence of
embolic complications during TAVI. A clinical trial with a
larger series of patientswill be necessary to confirm the safety
and efficacy of this embolic capture device in preventing
systemic embolization and neurologic complications during
either conventional cardiac surgery or transaortic TAVI.References
1. Blauth CI, Cosgrove DM, Webb BW, Ratliff NB, Boylan M, Piedmonte MR,
et al. Atheroembolism from the ascending aorta. An emerging problem in
cardiac surgery. J Thorac Cardiovasc Surg. 1992;103:1104-11; discussion
1111-2.
2. Calafiore AM, Di Mauro M, Teodori G, Di Giammarco G, Cirmeni S, Contini M,
et al. Impact of aortic manipulation on incidence of cerebrovascular accidents af-
ter surgical myocardial revascularization. Ann Thorac Surg. 2002;73:1387-93.
3. Barbut D, Hinton RB, Szatrowski TP, Hartman GS, Bruefach M, Williams-
Russo P, et al. Cerebral emboli detected during bypass surgery are associated
with clamp removal. Stroke. 1994;25:2398-402.
4. Barbut D, Yao FS, Lo YW, Silverman R, Hager DN, Trifiletti RR, et al. Determi-
nation of size of aortic emboli and embolic load during coronary artery bypass
grafting. Ann Thorac Surg. 1997;63:1262-7.
5. Barbut D, Lo YW, Gold JP, Trifiletti RR, Yao FS, Hager DN, et al. Impact of
embolization during coronary artery bypass grafting on outcome and length of
stay. Ann Thorac Surg. 1997;63:998-1002.2910 The Journal of Thoracic and Cardiovascular Sur6. Roach GW, Kanchuger M, Mangano CM, NewmanM, Nussmeier N, Wolman R,
et al. Adverse cerebral outcomes after coronary bypass surgery. Multicenter
Study of Perioperative Ischemia Research Group and the Ischemia Research
and Education Foundation Investigators. N Engl J Med. 1996;335:1857-63.
7. Nuis RJ, Piazza N, Van Mieghem NM, Otten AM, Tzikas A, Schultz CJ, et al.
In-hospital complications after transcatheter aortic valve implantation revisited
according to the valve academic research consortium definitions. Catheter Car-
diovasc Interv. 2011;78:457-67.
8. Grube E, Schuler G, Buellesfeld L, Gerckens U, Linke A, Wenaweser P, et al.
Percutaneous aortic valve replacement for severe aortic stenosis in high-risk pa-
tients using the second- and current third-generation self-expanding CoreValve
prosthesis: device success and 30-day clinical outcome. J Am Coll Cardiol.
2007;50:69-76.
9. Himbert D, Descoutures F, Al-Attar N, Iung B, Ducrocq G, Detaint D, et al. Re-
sults of transfemoral or transapical aortic valve implantation following a uniform
assessment in high-risk patients with aortic stenosis. J Am Coll Cardiol. 2009;54:
303-11.
10. Lefevre T, Kappetein AP, Wolner E, Nataf P, Thomas M, Sch€achinger V, et al.;
PARTNER EU Investigator Group. One year follow-up of the multi-centre Euro-
pean PARTNER transcatheter heart valve study. Eur Heart J. 2011;32:148-57.
11. Eggebrecht H, Schmermund A, Voigtl€ander T, Kahlert P, Erbel R, Mehta RH.
Risk of stroke after transcatheter aortic valve implantation (TAVI): a meta-
analysis of 10,037 published patients. EuroIntervention. 2012;8:129-38.
12. Smith CR, LeonMB,MackMJ,Miller DC,Moses JW, Svensson LG, et al. Trans-
catheter versus surgical aortic-valve replacement in high-risk patients. N Engl J
Med. 2011;364:2187-98.
13. Kahlert P, Knipp SC, Schlamann M, Thielmann M, Al-Rashid F, Weber M, et al.
Silent and apparent cerebral ischemia after percutaneous transfemoral aortic
valve implantation: a diffusion-weighted magnetic resonance imaging study.Cir-
culation. 2010;121:870-8.
14. Harringer W. Capture of particulate emboli during cardiac procedures in which
aortic cross-clamp is used. International Council of Emboli Management Study
Group. Ann Thorac Surg. 2000;70:1119-23.
15. Reichenspurner H, Navia JA, Berry G, Robbins RC, Barbut D, Gold JP, et al. Par-
ticulate emboli capture by an intra-aortic filter device during cardiac surgery. J
Thorac Cardiovasc Surg. 2000;119:233-41.
16. Schmitz C, Weinreich S, White J, Oengoeren I, Schneider R, Schneider D, et al.
Can particulate extraction from the ascending aorta reduce neurologic injury in
cardiac surgery? J Thorac Cardiovasc Surg. 2003;126:1829-38.
17. Banbury MK, Kouchoukos NT, Allen KB, Slaughter MS, Weissman NJ,
Berry GJ, et al. Emboli capture using the Embol-X intraaortic filter in cardiac sur-
gery: a multicentered randomized trial of 1,289 patients. Ann Thorac Surg. 2003;
76:508-15; discussion 515.
18. Schmitz C, Blackstone EH, International Council of Emboli Management
(ICEM) Study Group. International Council of Emboli Management (ICEM)
Study Group results: risk adjusted outcomes in intraaortic filtration. Eur J Car-
diothorac Surg. 2001;20:986-91.
19. Stolz E, Gerriets T, Kluge A, Klovekorn WP, Kaps M, Bachmann G. Diffusion-
weighted magnetic resonance imaging and neurobiochemical markers after
aortic valve replacement: implications for future neuroprotective trials? Stroke.
2004;35:888-92.
20. Knipp SC, Matatko N, Schlamann M, Wilhelm H, Thielmann M, Forsting M,
et al. Small ischemic brain lesions after cardiac valve replacement detected by
diffusion-weighted magnetic resonance imaging: relation to neurocognitive
function. Eur J Cardiothorac Surg. 2005;28:88-96.
21. Nietlispach F, Wijesinghe N, Gurvitch R, Tay E, Carpenter JP, Burns C, et al. An
embolic deflection device for aortic valve interventions. JACCCardiovasc Interv.
2010;3:1133-8.
22. Christenson JT, Vala DL, Licker M, Sierra J, Kalangos A. Intra-aortic filtration
capturing particulate emboli during aortic cross-clamping. Tex Heart Inst J.
2005;32:515-21.
23. Gerriets T, Schwarz N, Sammer G, Baehr J, Stolz E, Kaps M, et al. Protecting the
brain from gaseous and solid micro-emboli during coronary artery bypass graft-
ing: a randomized controlled trial. Eur Heart J. 2010;31:36-8.
24. Bagur R, Rodes-Cabau J, Doyle D, De Larochelliere R, Villeneuve J,
Bertrand OF, et al. Transcatheter aortic valve implantation with ‘‘no touch’’ of
the aortic arch for the treatment of severe aortic stenosis associated with complex
aortic atherosclerosis. J Card Surg. 2010;25:501-3.
25. Etienne PY, Papadatos S, Pieters D, Khoury EE, Alexis F, Price J, et al. Embol-X
intraaortic filter and transaortic approach for improved cerebral protection in
transcatheter aortic valve implantation. Ann Thorac Surg. 2011;92:e95-6.gery c December 2014
